Related Experiment Video
Updated: May 18, 2026

Contrast-Enhanced Subharmonic Aided Pressure Estimation (SHAPE) Using Ultrasound Imaging with a Focus on Identifying Portal Hypertension
Published on: December 5, 2020
Use of partial AUC (PAUC) to evaluate bioequivalence--a case study with complex absorption: methylphenidate
Jeanne Fourie Zirkelbach1, Andre J Jackson, Yaning Wang
1Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation & Research Food & Drug Administration, 10903 New Hampshire Ave, Silver Spring, Maryland 20993, USA.
Purpose:
Methylphenidate modified-release products produce early and late peak concentrations critical for treatment of morning and afternoon symptoms of attention deficit hyperactivity disorder (ADHD). Standard bioequivalence (BE) criteria cannot be applied to these products. The performance of partial area under the drug concentration-time curve (PAUC), Cmax and AUCINF to assess BE were independently evaluated for two products.
Methods:
A two-stage analysis was performed on plasma data for two methylphenidate modified-release products (Product 1 and 2). Simulations using the fitted parameters determined how changes in fast absorption rate constant (K0Fast) and fraction available (F1) affected curve shape and BE determination using Cmax, AUCINF and PAUC.
Results:
The sensitivity of the mean PAUC(test)/PAUC(reference) ratios to changes in K0Fast(test) are product dependent. Product 1 mean PAUC(test)/PAUC(reference) ratios for PAUC0-4h are more responsive to both decreases and increases in K0Fast(test) than Product 2. Product 2 showed a greater response in the mean PAUC(test)/PAUC(reference) ratio for PAUC0-4h when the K0Fast(test) is decreased and less response as the value is increased.
Conclusions:
PAUC estimated curve shape is sensitive to changes in absorption and are product specific, and may require a new PAUC metric for each drug. A non-product specific metric to assess curve shape is warranted.
Related Concept Videos
Bioequivalence Data: Statistical Interpretation
Measurement of Bioavailability: Pharmacodynamic Methods
Measurement of Bioavailability: Pharmacokinetic Methods
Bioavailability Study Design: Absolute Versus Relative Bioavailability
Dosage Regimens: Partial Pharmacokinetic Parameters
Bioavailability Study Design: Single Versus Multiple Dose Studies
